RECRUITING

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.

Official Title

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Quick Facts

Study Start:2018-09-25
Study Completion:2038-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04174157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients treated with OAV-101 with a genetically confirmed diagnosis of SMA regardless of the date of diagnosis.
  2. * Appropriate consent/assent has been obtained for participation in the registry
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Novartis Gene Therapies
CONTACT
1-888-669-6682
novartis.email@novartis.com
Novartis Gene Therapies
CONTACT
+4161324111

Principal Investigator

Novartis Pharmaceuticals
STUDY_DIRECTOR
Novartis Pharmaceuticals

Study Locations (Sites)

Phoenix Children's Hospital
Phoenix, Arizona, 85016
United States
Arkansas Children's Hospital
Little Rock, Arkansas, 72202
United States
Loma Linda University Health
Loma Linda, California, 92350
United States
Children's Hospital of Los Angeles
Los Angeles, California, 90027
United States
University of California Los Angeles Health
Los Angeles, California, 90095
United States
Valley Children's Healthcare
Madera, California, 93636
United States
Children's Hospital of Orange County
Madera, California, 93638
United States
University of California Davis Health System
Sacramento, California, 95817
United States
Rady Children's Hospital San Diego
San Diego, California, 92123
United States
Children's Hospital Colorado
Aurora, Colorado, 80045
United States
Connecticut Children's Medical Center
Farmington, Connecticut, 06034
United States
Yale-New Haven Health System
New Haven, Connecticut, 06510
United States
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida, 33908
United States
Nicklaus Children's Hospital
Miami, Florida, 33155
United States
Adventist Health System - Florida
Orlando, Florida, 32803
United States
Jackson South Medical Center
Palmetto Bay, Florida, 33157
United States
Indiana University Health University Hospital (IUHUH)
Indianapolis, Indiana, 46202
United States
University of Iowa
Iowa City, Iowa, 52242-1009
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
University of Louisville
Louisville, Kentucky, 40202
United States
University of Minnesota
Minneapolis, Minnesota, 55455
United States
University of Missouri Health System
Columbia, Missouri, 65212
United States
Washington University School of Medicine in St. Louis
Saint Louis, Missouri, 63110
United States
Atlantic Health System
Morristown, New Jersey, 07960
United States
University of Rochester Medical Center
Rochester, New York, 14642
United States
The State University of New York
Stony Brook, New York, 11794
United States
Duke Health
Durham, North Carolina, 27705
United States
Akron Children's Hospital
Akron, Ohio, 44308-1062
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3026
United States
University Hospitals
Cleveland, Ohio, 44106
United States
Nationwide Children's Hospital
Columbus, Ohio, 43205
United States
Oklahoma University Medical Center
Oklahoma City, Oklahoma, 73104
United States
Oregon Health and Science University
Portland, Oregon, 97239-3098
United States
Penn State Hershey
Hershey, Pennsylvania, 17033
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15224
United States
Prisma Health
Greenville, South Carolina, 29615
United States
Methodist Le Bonheur Healthcare
Memphis, Tennessee, 38103
United States
Child Neurology Consultants of Austin
Austin, Texas, 78731
United States
Children's Health
Dallas, Texas, 75207
United States
Cook Children's
Fort Worth, Texas, 76104
United States
Texas Children's Hospital
Houston, Texas, 77030
United States
CHRISTUS Health
San Antonio, Texas, 78207
United States
University of Utah
Salt Lake City, Utah, 84113
United States
University of Virginia Health System
Charlottesville, Virginia, 22908
United States
Children's Hospital of The King's Daughters
Norfolk, Virginia, 23507
United States
Virginia Commonwealth University Health System
Richmond, Virginia, 23298
United States
Seattle Children's
Seattle, Washington, 98105
United States
MultiCare Health System
Tacoma, Washington, 98405
United States
University of Wisconsin
Madison, Wisconsin, 53792
United States
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Novartis Pharmaceuticals

  • Novartis Pharmaceuticals, STUDY_DIRECTOR, Novartis Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-09-25
Study Completion Date2038-06-30

Study Record Updates

Study Start Date2018-09-25
Study Completion Date2038-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Spinal Muscular Atrophy (SMA)